Tissue engineered blood vessels

• US 8,491,457 B2
• Filed: 03/10/2006
• Issued: 07/23/2013
• Est. Priority Date: 03/11/2005
• Status: Active Grant

• Current Assignee: Wake Forest University Health Sciences
• Original Assignee: Wake Forest University Health Sciences
• Inventors: Atala, Anthony, Soker, Shay, Yoo, James
• Primary Examiner(s): FORD, ALLISON M
• Application Number:
  US11/372,743
• Publication Number:
  US 20060240061A1
• Time in Patent Office: 2,692 Days
• Field of Search: None
• US Class Current: 600/36
• CPC Class Codes: A61F 2/06 Blood vessels
• CPC Class Codes: A61F 2/062 Apparatus for the production of blood vessels made from natural tissue or with layers of living cells prostheses made from natural tissue or living cells A61L27/507
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3808 Endothelial cells
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The invention is directed to methods for preparing artificial blood vessels by preconditioning a matrix seeded with endothelial cells to fluid flow conditions that mimic blood flow.

Claims

1. A method for producing a preconditioned blood vessel, comprising:

providing a biocompatible matrix shaped in a tubular configuration seeded with a cultured population of endothelial cells on the inside surface of the matrix, wherein the tubular matrix comprises at least one nanoparticle coupled to a releasable therapeutic agent which is incorporated within the tubular matrix;

attaching a first and second end of the tubular matrix to a first and second attachment element in a preconditioning chamber, wherein the first and second attachment elements have a channel that is fluidly coupled to a fluid flow system; and

preconditioning the seeded tubular matrix with the flow system by moving a biological fluid through the seeded tubular matrix, wherein the flow-rate and pulse-rate of the biological fluid is controlled such that the preconditioned blood vessel is produced.

2. The method of claim 1, wherein the step of preconditioning the matrix comprises moving the biological fluid through the inside surface of the seeded tubular matrix in a closed fluid flow system.

3. The method of claim 1, wherein the step of providing a biocompatiable matrix further comprises:

providing a biocompatible matrix shaped in a tubular configuration seeded with a cultured population of endothelial cells on the inside surface of the matrix, wherein the tubular matrix comprises at least one natural component from about 25 percent to about 75 percent by weight.

4. The method of claim 1, further comprising:

seeding the tubular matrix with a cultured population of endothelial cells on the inside surface of the matrix; and

seeding the tubular matrix with a population of smooth muscle cells on the outside surface of the matrix.

5. The method of claim 1, wherein the step of preconditioning the seeded tubular matrix further comprises moving a biological fluid having a composition and viscosity that mimics blood through the inside surface of the attached matrix as a pulsed flow to induce a wall shear stress of at least 10 dynes/cm² so that the seeded matrix is exposed to fluid flow conditions that mimic flow of blood through a native blood vessel.

6. The method of claim 1, wherein the method further comprises continuing exposure of the cells on the inside surface of the matrix to the pulsed fluid flow to allow the seeded cells to develop under fluid flow conditions until the matrix can withstand a wall pressure distribution of at least 60 mmHg.

7. The method of claim 1, wherein biocompatible matrix is selected from the group consisting of a decellularized matrix, an electrospun matrix and a synthetic polymer matrix.

8. The method of claim 1, wherein the preconditioning chamber is a container with dimensions suitable for attaching a length of tubular matrix.

9. The method of claim 1, wherein the pulsed flow has a pulse-rate that is varied over time to induce a wall shear stress in the range of about 10 dynes/cm² to about 45 dynes/cm² .

10. The method of claim 1, wherein the pulsed flow has a pulse-rate that is varied over time to induce a wall pressure distribution in the range of about 60 to about 200 mmHg.

11. The method of claim 1, wherein the biological fluid is moved through the seeded tubular matrix by a pump.

12. The method of claim 1, wherein the biological fluid is selected from the group consisting of culture medium, buffer medium, and physiological medium.

13. The method of claim 1, further comprising adding a volume of biological fluid to the preconditioning chamber such that the outside surface of the tubular matrix is exposed to the biological fluid.

14. The method of claim 1, wherein the tubular matrix is an electrospun matrix comprising at least one natural component and at least one synthetic polymer component.

15. The method of claim 14, wherein the natural component is collagen and the synthetic polymer component is poly(lactide-co-glycolides) (PLGA).

16. The method of claim 1, wherein the matrix comprises elastin.

17. The method of claim 1, further comprises applying radiation to heat the nanoparticle.

18. The method of claim 17, wherein the step of applying radiation comprises applying radiation at a wavelength in the range of about 700 nm to about 1000 nm to release the therapeutic agent from the nanoparticle.

19. The method of claim 1, wherein the matrix further comprises an image enhancing agent.

20. The method of claim 19, wherein the image enhancing agent is gadolinium.

21. The method of claim 1, wherein the endothelial cells are isolated from a human saphenous vein.

22. The method of claim 1, wherein the endothelial cells are derived from progenitor cells isolated from peripheral blood or bone marrow.

23. The method of claim 1, further comprising:

evaluating production of at least one vasoactive agent from the pre-conditioned seeded tubular matrix, wherein production of at least one vasoactive agent indicates the preconditioned blood vessel is produced.